📰 ReutersReutersCodex · 实盘不做把握 5/10
北京时间·🕒 发布 07-31 13:20:09时区推断·⟳ 抓取 07-31 13:21:06·⚡ 决策 08-01 07:42:54 +18h21m·87.7 天前
西门子医疗因中国诊断业务疲弱下调2026财年收入增长指引但上调EPS指引
本次核心负面是2026财年收入增长指引从4.5%–5.0%下调至3.5%–4.0%，原因仍是中国体外诊断市场集采和报销下调导致价格与销量承压。
📄 原文Reuters↗ 原文
Medical technology firm Siemens Healthineers (SHLG.DE) cut its 2026 revenue growth forecast on Friday to a range of 3…
不做 西门子医疗（SHL.DE）
收入下修与EPS上修并存，且中国诊断业务压力5月已披露；德国市场已完整交易一日，stock_quote未能返回7月31日可回测现价，不满足强空催化和可执行价格条件，当前不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司二季报已披露中国诊断市场结构性变化，并将2026财年收入增长指引从5%–6%下调至4.5%–5.0%，说明本次压力不是全新变量。市场反应:当时Reuters转述称公司股价盘中一度下跌约3.3%。
- 公司Q3材料确认收入增长指引降至3.5%–4.0%，调整后EPS指引升至2.35–2.45欧元，且说明EPS上修来自约0.15欧元关税退款贡献。
- Reuters在德国开盘前转述收入指引下修、EPS指引上修及Q3收入小幅低于LSEG一致预期，形成主流市场扩散。
- WSJ同日归纳为混合业绩：诊断业务拖累收入指引，但调整后EBIT和EPS受关税退款支撑。市场反应:页面标注SHL约-0.91%，但行情口径与本地工具不完全一致。
关键理由
- 本次核心负面是2026财年收入增长指引从4.5%–5.0%下调至3.5%–4.0%，原因仍是中国体外诊断市场集采和报销下调导致价格与销量承压。
- 负面并非全新主题：公司5月7日二季报已因同一中国诊断市场结构性变化把收入指引从5%–6%下修至4.5%–5.0%，本次是同一压力的延续。
- 同一公告同时把调整后EPS指引上调至2.35–2.45欧元，且Q3调整后EBIT和利润率受美国关税退款支撑，削弱了做空的净损害强度。
主要风险
- 若下季诊断业务继续中个位数下滑且关税退款不可持续，收入下修可能转化为2027财年盈利下修。
- 当前已过德国市场完整交易日且股票报价服务未能返回7月31日收盘价，无法构造可回测的低滑点短线入场。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-07-31 · 影响 weakens
公司Q3调整后EPS同比增长至0.70欧元，调整后EBIT利润率升至19.1%，全年EPS指引因关税退款上调，削弱收入下修的净空头强度。
检索:Siemens Healthineers Q3 2026 EPS raised tariff refunds EBIT beat order book counter evidence 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-31 · 影响 invalidates
诊断业务Q3收入同比下降5.5%，中国收入下降10%，公司还预计Q4诊断业务继续中个位数下滑，反证不足以支持做多。
检索:Siemens Healthineers diagnostics China procurement revenue forecast cut July 2026 bearish evidence 原文 ↗ - 做空前查反向 · 来源 kb_search · 影响 none
内部KB检索超时，未取得可用的额外反向或敞口证据；不把未命中当作事件不存在。
检索:西门子医疗 中国 IVD 集采 体外诊断 结构性变化 2026 Q3 revenue outlook EPS tariff refunds
工具调用 · 历史记录,结果未知(5 种)
- search_processed_events · 结果未知
- normalize_ticker · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- price_snapshot · 结果未知
原文全文
展开原文 · 873 字
Medical technology firm Siemens Healthineers (SHLG.DE) cut its 2026 revenue growth forecast on Friday to a range of 3.5% to 4.0%, as China's procurement policy weighs on its diagnostics business.
China's volume-based procurement and lower reimbursement rates have depressed prices and sales volumes in the country's diagnostics market.
The German company also raised outlook for adjusted earnings per share to between €2.35 and €2.45, reflecting the amount of U.S. tariff refunds
It had previously forecast annual revenue growth of 5% to 6% and earnings per share in a range of €2.20 to €2.40
Its third-quarter revenue rose 1.8% to €5.76 billion ($6.63 billion) and missed an LSEG consensus estimate by 0.8%
The Erlangen-based firm also posted a year-on-year increase in its adjusted operating profit margin to 19.1% from 16.8%
($1 = 0.8692 euros)
China's volume-based procurement and lower reimbursement rates have depressed prices and sales volumes in the country's diagnostics market.
The German company also raised outlook for adjusted earnings per share to between €2.35 and €2.45, reflecting the amount of U.S. tariff refunds
It had previously forecast annual revenue growth of 5% to 6% and earnings per share in a range of €2.20 to €2.40
Its third-quarter revenue rose 1.8% to €5.76 billion ($6.63 billion) and missed an LSEG consensus estimate by 0.8%
The Erlangen-based firm also posted a year-on-year increase in its adjusted operating profit margin to 19.1% from 16.8%
($1 = 0.8692 euros)
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。